Advances in Medications for Breast Cancer Leptomeningeal Metastases

doi:10.19803/j.1672-8629.20250786

Abstract

Abstract: Objective To summarize the latest research advances in precision detection, biomarkers, and treatment strategies for breast cancer leptomeningeal metastasis (BCLM) in order to provide references for improving the clinical efficacy and prognosis of patients. Methods An in-depth analysis of the mechanisms underlying BCLM was conducted based on the molecular diagnostic techniques, prognostic biomarkers, as well as therapeutic strategies. Current challenges to diagnostic approaches and treatment strategies were also studied. Results Based on advancements in novel detection technologies, individualized treatment strategies guided by biomarkers promised wide applications. Furthermore, new targeted drugs and delivery technologies offered more opportunities to improve patients’ prognosis. Conclusion The clinical management of BCLM should integrate precision testing, biomarker-guided approaches, and multimodal treatment strategies. High-quality clinical studies are essential to optimizing therapeutic frameworks and prolonging patients’ survival.

Key words: Breast Cancer, Leptomeningeal Metastasis, Diagnostic Techniques, Biomarkers, Therapeutic Drugs

CLC Number:

R979.1

YE Ling, XU Rui, RUAN Cong, QIAN Jiajia, HU Weiqiong, WANG Qiru, LIU Jiyong, LI Gang. Advances in Medications for Breast Cancer Leptomeningeal Metastases[J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 229-234.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250786

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I2/229

References

[1] SCHWARZOVA K, LI X, ADEKUNLE F, et al.Leptomeningeal Carcinomatosis: a Rare Presentation of Perforated Gastric Cancer[J]. Cureus, 2023, 15(11): e48775.
[2] LAMBA N, CAGNEY DN, CATALANO PJ, et al.Incidence Proportion and Prognosis of Leptomeningeal Disease among Patients with Breast vs Non-Breast Primaries[J]. Neuro-Oncology, 2023, 25(5): 973-983.
[3] WANG YY, YING XH, ZHANG KY, et al.Leptomeningeal Metastasis in Triple-Negative Breast Cancer: a Retrospective Study[J]. Discover Oncology, 2025, 16(1): 1470.
[4] WHITELEY AE, MA D, WANG L, et al. Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis[J]. Science, 2024, 384(6702): eadh5548.
[5] PAN JK, LIN WD, KUO YL, et al.ICAM2 Initiates Trans-Blood-CSF Barrier Migration and Stemness Properties in Leptomeningeal Metastasis of Triple-Negative Breast Cancer[J]. Oncogene, 2023, 42(39): 2919-2931.
[6] BOIRE A, ZOU Y, SHIEH J, et al. Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis[J]. Cell, 2017, 168(6): 1101-1113. e13.
[7] LE RHUN E, WELLER M, BRANDSMA D, et al. EANO-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Patients with Leptomeningeal Metastasis from Solid Tumours[J]. Annals of Oncology, 2017, 28(Suppl 4): iv84-iv99.
[8] BȌNIG L, MȌHN N, AHLBRECHT J, et al. Leptomeningeal Metastasis: the Role of Cerebrospinal Fluid Diagnostics[J]. Frontiers in Neurology, 2019, 10: 839.
[9] ANGUS L, DEGER T, JAGER A, et al.Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases[J]. Clinical Cancer Research, 2021, 27(10): 2798-2806.
[10] TORRE M, LEE EQ, CHUKWUEKE UN, et al.Integration of Rare Cell Capture Technology into Cytologic Evaluation of Cerebrospinal Fluid Specimens from Patients with Solid Tumors and Suspected Leptomeningeal Metastasis[J]. Journal of the American Society of Cytopathology, 2020, 9(1): 45-54.
[11] WOOSTER M, MCGUINNESS JE, FENN KM, et al.Diagnosis of Leptomeningeal Metastasis in Women with Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide^TM Assay[J]. Clinical Breast Cancer, 2022, 22(4): e457-e462.
[12] ZHENG MM, ZHOU Q, CHEN HJ, et al.Cerebrospinal Fluid Circulating Tumor DNA Profiling for Risk Stratification and Matched Treatment of Central Nervous System Metastases[J].Nature Medicine, 2025, 31(5): 1547-1556.
[13] KHALIL M, TEUNISSEN CE, LEHMANN S, et al.Neurofilaments as Biomarkers in Neurological Disorders-Towards Clinical Applica-tion[J]. Nature Reviews, Neurology, 2024, 20(5): 269-287.
[14] HYUN JW, KIM Y, KIM KH, et al.Cerebrospinal Fluid Neurofilament Light Chain as a Potential Prognostic Biomarker for Leptomeningeal Metastasis[J]. Oncology Letters, 2022, 24(6): 428.
[15] LEE KY, IM JH, LIN W, et al.Nanoparticles in 472 Human Cerebro-spinal Fluid: Changes in Extracellular Vesicle Concentration and miR-21 Expression as a Biomarker for Leptomeningeal Metastasis[J]. Cancers (Basel), 2020, 12(10): 2745.
[16] CHEW SM, SEIDMAN AD.New Strategies for the Treatment of Breast Cancer with Leptomeningeal Metastasis[J]. Current Opinion in Oncology, 2023, 35(6): 500-506.
[17] O'BRIEN BJ, MURTHY RK, BERRY DA, et al. Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer with Leptomeningeal Metastasis[C]. Chicago: ASCO Annual Meeting, 2024.
[18] ALDER L, TRAPANI D, BRADBURY C, et al.Durable Responses in Patients with HER2+ Breast Cancer and Leptomeningeal Metastases Treated with Trastuzumab Deruxtecan[J]. NPJ Breast Cancer, 2023, 9(1): 19.
[19] YANG Y, WANG S, MA P, et al.Drug Conjugate-Based Anticancer Therapy-Current Status and Perspectives[J]. Cancer Letters, 2023, 552: 215969.
[20] WANG M, LIU J, XIA M, et al.Peptide-Drug Conjugates: a New Paradigm for Targeted Cancer Therapy[J]. European Journal of Medicinal Chemistry, 2024, 265: 116119.
[21] SU Z, XIAO D, XIE F, et al.Antibody-Drug Conjugates: Recent Advan-ces in Linker Chemistry[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3889-3907.
[22] KUMTHEKAR P, TANG SC, BRENNER AJ, et al.ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases[J]. Clinical Cancer Research, 2020, 26(12): 2789-2799.
[23] PREUSSER M, GARDE-NOGUERA J, GARCÍA-MOSQUERA JJ, et al. Patritumab Deruxtecan in Leptomeningeal Metastatic Disease of Solid Tumors: the Phase 2 TUXEDO-3 Trial[J]. Nature Medicine, 2025, 31(8): 2797-2805.
[24] MILLS MN, KING W, SOYANO A, et al.Evolving Management of HER2+ Breast Cancer Brain Metastases and Leptomeningeal Disease[J]. Journal of Neuro-Oncology, 2022, 157(2): 249-269.
[25] SRINIVASALU VK, SUBRAMANIAM N, PHILIP A, et al.Triple Intrathecal Chemotherapy for Leptomeningeal Carcinomatosis in Solid Tumors: Treatment Outcomes, Response and Their Determinants[J]. Indian Journal of Cancer, 2021, 58(1): 84-90.
[26] OBERKAMPF F, GUTIERREZ M, TRABELSI GRATI O, et al.PhaseⅡ Study of Intrathecal Administration of Trastuzumab in Patients with HER2-Positive Breast Cancer with Leptomeningeal Metastasis[J]. Neuro-Oncology, 2023, 25(2): 365-374.
[27] KUMTHEKAR PU, AVRAM MJ, LASSMAN AB, et al.a Phase Ⅰ/Ⅱ Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmaco-kinetics[J]. Neuro-Oncology, 2023, 25(3): 557-565.
[28] AHMED KA, KUMTHEKAR PU, PINA Y, et al.Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: a Phase 1 Nonrandomized Controlled Trial[J]. JAMA Oncology, 2024, 10(7): 984-986.
[29] PORTNOW J, BLANCHARD S, KILPATRICK J, et al.a Phase 1 Study of Intraventricularly Administered Autologous HER2-Targeting Chimeric Antigen Receptor T Cells(HER2-CAR T cells), with and without Lymphodepletion, in HER2-Positive Breast Cancer Patients with Recurrent Brain and/or Leptomeningeal Metastases[C]. Shanghai: Society of Neuro-Oncology Annual Meeting(神经肿瘤学会年会), 2025.
[30] ASHRAFZADEH-KIAN S, FIGDORE D, LARSON B, et al.Head-to-Head Comparison of Four Plasma Neurofilament Light Chain (NfL) Immunoassays[J]. Clinica Chimica Acta, 2024, 561: 119817.
[31] CABEZAS-CAMARERO S, PÉREZ-ALFAYATE R, GARCÍA-BARBERÁN V, et al. ctDNA Detection in Cerebrospinal Fluid and Plasma and Mutational Concordance with the Primary Tumor in a Multicenter Prospective Study of Patients with Glioma[J]. Annals of Oncology, 2025, 36(6): 660-672.
[32] FILHO OM, VIALE G, STEIN S, et al.Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab[J]. Cancer Discovery, 2021, 11(10): 2474-2487.
[33] MOSELE F, DELUCHE E, LUSQUE A, et al.Trastuzumab Deruxtecan in Metastatic Breast Cancer with Variable HER2 Expression: the Phase 2 DAISY Trial[J]. Nature Medicine, 2023, 29: 2110-2120.
[34] SALEH K, KHOURY R, KHALIFE N, et al.Mechanisms of Action and Resistance to Anti-HER2 Antibody-Drug Conjugates in Breast Cancer[J]. Cancer Drug Resistance, 2024, 7: 22.
[35] FITZPATRICK A, IRAVANI M, MILLS A, et al.Genomic Profiling and Pre-Clinical Modelling of Breast Cancer Leptomeningeal Metastasis Reveals Acquisition of a Lobular-Like Phenotype[J]. Nature Comm-unications, 2023, 14(1): 7408.
[36] MAGBANUA MJ, MELISKO M, ROY R, et al.Molecular Profiling of Tumor Cells in Cerebrospinal Fluid and Matched Primary Tumors from Metastatic Breast Cancer Patients with Leptomeningeal Carcinomatosis[J]. Cancer Research, 2013, 73(23): 7134-7143.
[37] XU X, YU T, WANG Z.Combining Antibody-Drug Conjugates with Immune Checkpoint Inhibitors: a New Paradigm for Breast Cancer Therapy[J]. Cancer Treatment Reviews, 2025, 140: 103012.
[38] YIN L, ZHOU S, ZHANG H, et al.Reprogramming the Tumor Microenvironment: Synergistic Mechanisms of Antibody-Drug Conjugates and Immune Checkpoint Inhibitors[J]. Antibody Therapeutics, 2025, 8(3): 262-274.
[39] NICOLÒ E, GIUGLIANO F, ASCIONE L, et al.Combining Antibody-Drug Conjugates with Immunotherapy in Solid Tumors: Current Landscape and Future Perspectives[J]. Cancer Treatment Reviews, 2022, 106: 102395.
[40] KURUPPU D, BHERE D, FARRAR CT, et al.Oncolytic HSV1 Targets Different Growth Phases of Breast Cancer Leptomeningeal Metas-tases[J]. Cancer Gene Therapy, 2023, 30(6): 833-844.
[41] BOYÉ K, GERALDO LH, FURTADO J, et al.Endothelial Unc5B Controls Blood-Brain Barrier Integrity[J]. Nature Communications, 2022, 13(1): 1169.